Protein therapies and antiproliferatives: A new paradigm in immunosuppression

Transplantation Reviews

Volumn 19, Issue 4, 2005, Pages 179-185

  Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD40 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE RECEPTOR AGONIST; CYTOKINE RECEPTOR ANTAGONIST; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; EVEROLIMUS; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15 ANTAGONIST; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 2 RECEPTOR STIMULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PROTEIN TARGETING; SIDE EFFECT; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

EID: 31644437625     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2005.10.006     Document Type: Article

References (59)

1. S. Hariharan C.P. Johnson B.A. Breshahan et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996 N Engl J Med 342 2000 605-612
2. S. Hariharan M.A. McBride W.S. Cherikh et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival Kidney Int 62 2002 311-318
3. H.U. Meier-Kriesche J.D. Schold B. Kaplan et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era Am J Transplant 2004 378-383
4. S. Hariharan Long-term kidney transplant survival Am J Kidney Dis 38 6 Suppl 6 2001 S44-S50
5. US renal data system. USRDS 2000 Annual Data Report: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease 2000.
6. K. Solez R.A. Axelsen H. Benediktsson et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology Kidney Int 44 1993 411-422
7. L.C. Racusen K. Solez R.B. Colvin et al. The Banff 97 working classification of renal allograft pathology Kidney Int 55 1999 713-723
8. S. Hariharan M.A. McBride E. Cohen Evolution of endpoints for renal transplant outcome Am J Transplant 3 2003 933-941
9. R.Y. Calne D.J. White The use of cyclosporine A in clinical organ grafting Ann Surg 196 1982 330-337
10. G.L. Plosker R.H. Foster Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation Drugs 59 2000 323-389
11. B.J. Nankivell R.J. Borrows C.L. Fung et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology Transplantation 78 2004 557-565
12. T.G. Peters K.N. Spinola J.C. West et al. Differences in patient and transplant professional perceptions of immunosuppression-induced cosmetic side effects Transplantation 78 2004 537-543
13. M. Mihatsch B. Ryffel F. Gudat The differential diagnosis between rejection and cyclosporine toxicity Kidney Int 52 1995 S63-S69
14. K. Solez F. Vincenti R. Filo Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group Transplantation 66 1998 1736-1740
15. B. Myers F. Newton Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury J Am Soc Nephrol 2 Suppl 1 1991 S45
16. W.M. Bennett A. DeMattos M.M. Meyer et al. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy Kidney Int 50 1996 1089-1100
17. B.J. Nankivell R.J. Borrows C.L. Fung et al. The natural history of chronic allograft nephropathy N Engl J Med 349 2003 2326-2333
18. T. Taniguchi Y. Minami The IL-2/IL-2 receptor system: A current overview Cell 73 1993 5-8
19. T. Franklin J. Cook The inhibition of nucleic acid synthesis by mycophenolic acid Biochem J 113 1969 515-524
20. F. Vincenti E. Ramos C. Brattstrom et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation Transplantation 71 2001 1282-1287
21. H.T. Tran M.K. Acharya D.B. McKay et al. Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids J Am Soc Nephrol 11 2000 1903-1909
22. S.M. Flechner S.M. Kurian K. Solez et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years Am J Transplant 4 2004 1776-1785
23. M. Pescovitz F. Vincenti M. Hart et al. Pharmacokinetics, safety and efficacy of mycophenolate mofetil in combination with sirolimus vs. cyclosporine in renal transplant patients Am J Transpl 4 Suppl 8 2004 251 [abstract #341]
24. S. Sehgal Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin Biochem 31 1998 335-340
25. M.Q. Xia G. Hale H. Waldmann Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen Mol Immunol 30 1993 1089-1096
26. A.D. Kirk D.A. Hale R.B. Mannon et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H) Transplantation 76 2003 120-129
27. S.J. Knechtle J.D. Pirsch J. Fechner et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study Am J Transplant 3 2003 722-730
28. J. Moreno P.E. Lipsky Differential ability of fixed antigen-presenting cells to stimulate nominal antigen-reactive and alloreactive T4 lymphocytes J Immunol 136 1986 3579-3587
29. V. Bhardwaj M.J. Colston The processing and presentation of mycobacterial antigens by human monocytes Eur J Immunol 18 1988 691-696
30. D. Neujahr L.A. Turka Lymphocyte depletion as a barrier to immunological tolerance Contrib Nephrol 146 2005 65-72
31. X. Zheng A. Sánchez-Fueyo M. Sho et al. Favorably tipping the balance between cytopathic and regulatory cells to create transplantation tolerance Immunity 19 2003 503-514
32. P. Bretscher M. Cohn A theory of self-nonself discrimination Science 169 1970 1042-1049
33. C.D. Gimmi J.G. Gribben G.J. Freemen et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation Proc Natl Acad Sci U S A 90 1993 6586-6590
34. M.L. Baroja J. Madrenas Viewpoint: Therapeutic implications of CTLA-4 compartmentalization Amer J Transpl 3 2003 919-926
35. T. Walunas D.J. Lenschow C.Y. Bakker et al. CTLA-4 can function as a negative regulator of T cell activation Immunity 1 1994 405-413
36. J.L. Greene et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions J Biol Chem 271 1996 26762-26771
37. P.S. Linsley J.L. Greene W. Brady et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors Immunity 1 1994 793-801
38. M. Denton R.M. Reul V.R. Dharnidharka et al. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection Pediatr Transplant 2 1998 6-15
39. Y. Yang J.M. Wilson CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40 Science 273 1996 1862-1864
40. I.S. Grewal H.G. Foellmer K.O. Grewal et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis Science 273 1996 1864-1867
41. M.H. Sayegh L.A. Turka The role of T-cell costimulatory activation pathways in transplant rejection N Engl J Med 338 1998 1813-1821
42. N.S. Kenyon M. Chatzipetrou M. Masetti et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154 Proc Natl Acad Sci U S A 96 1999 8132-8137
43. A.D. Kirk L.C. Burkly D.S. Batty et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in non-human primates Nature Med 5 1999 686-693
44. P. Andre K.S. Prasad C.V. Denis et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism Nat Med 8 2002 247-252
45. A.D. Kirk S.J. Knechtle H.W. Sollinger et al. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation (abstract #223) Am J Transplant 1 Suppl 1 2001 190
46. F. Vincenti What's in the pipeline? New immunosuppressive drugs in transplantation Am J Transplant 2 2002 898-903
47. P.S. Linsley J.A. Ledbetter The role of the CD28 receptor during T cell responses to antigen Annu Rev Immunol 11 1993 191-212
48. J.M. Kremer R. Westhovens M. Leon et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig N Engl J Med 349 2003 1907-1915
49. J.A. Abrams M.G. Lebwohl C.A. Guzzo et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris J Clin Invest 103 1999 1243-1252
50. M.E. Russell W.W. Hancock E. Akalin et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis J Clin Invest 97 1996 833-838
51. A.D. Kirk D.M. Harlan N.N. Armstrong et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates Proc Natl Acad Sci U S A 94 1997 8789-8794
52. M.G. Levisetti P.A. Padrid G.L. Szot et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation J Immunol 159 1997 5187-5191
53. K.S. Kim M.D. Denton A. Chandraker et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis Am J Pathol 158 2001 977-986
54. T. Pentcheva-Hoang J.G. Egen K. Wojnoonski et al. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse Immunity 21 2004 401-413
55. C. Larsen T.C. Pearson A.B. Adams et al. Rational development of LEA29Y, a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties Am J Transplant 5 2005 423-424
56. F. Vincenti C. Larsen A. Durrbach et al. Costimulation blockade with belatacept in renal transplantation N Engl J Med 353 2005 770-781
57. B. Nashan J. Grinyo F. Vincenti et al. Co-stimulation blockade with LEA29Y in renal transplant: Improved renal function and CV/metabolic profile at 6 months compared with cyclosporine ATC 4 Suppl 8 2004 441 [Abstract #1035, May 14-19]
58. C.P. Larsen E.T. Elwood D.Z. Alexander et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways Nature 381 1996 434-438
59. A.B. Adams N. Shirasugi T.R. Jones et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival J Immunol 174 2005 542-550